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Abstract
Introduction: Inflammatory joint destruction in rheumatoid arthritis (RA) may be triggered by autoantibodies, the
production of which is supported by autoreactive T cells. Studies on RA and animal models of the disease suggest
that T cells recruited in the joints can locally initiate or propagate arthritis. Herein, we investigated the role of joint-
homing versus lymphoid organ-homing T cells in the development of proteoglycan-induced arthritis (PGIA), an
autoimmune model of RA.
Methods: To identify T cells migrating to the joints before and during development of autoimmune arthritis, we
transferred fluorescence-labeled T cells, along with antigen-presenting cells, from BALB/c mice with PGIA to naïve
syngeneic severe combined immunodeficient (SCID) mice. We then monitored the recruitment of donor T cells in
the ankle joints and joint-draining lymph nodes of the recipients using in vivo two-photon microscopy and ex vivo
detection methods. To limit T-cell access to the joints, we selectively depleted T cells in the blood circulation by
treatment with FTY720, an inhibitor of lymphocyte egress from lymphoid organs. Reduction of T cell presence in
both lymphoid organs and blood was achieved by injection of donor cells from which T cells were removed prior
to transfer. T and B cells were quantitated by flow cytometry, and antigen (PG)-specific responses were assessed by
cell proliferation and serum antibody assays.
Results: Despite development of adoptively transferred arthritis in the recipient SCID mice, we found very few
donor T cells in their joints after cell transfer. Treatment of recipient mice with FTY720 left the T-cell pool in the
lymphoid organs intact, but reduced T cells in both peripheral blood and joints. However, FTY720 treatment failed
to inhibit PGIA development. In contrast, arthritis was not seen in recipient mice after transfer of T cell-depleted
cells from arthritic donors, and serum autoantibodies to PG were not detected in this group of mice.
Conclusions: Our results suggest that antigen-specific T cells, which home to lymphoid organs and provide help
to B cells for systemic autoantibody production, play a greater role in the development and progression of
autoimmune arthritis than the small population of T cells that migrate to the joints.
Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune
disease involving mainly the peripheral synovial joints
and causing chronic inflammation and profound tissue
destruction in affected patients [1]. The autoimmune
character of RA is best supported by the presence of cir-
culating autoantibodies (autoAbs) against immunoglobu-
lins (rheumatoid factor), citrullinated proteins, and other
endogenous proteins [2,3], which may become detect-
able in serum years before the development of joint
symptoms [4]. The systemic production of autoAbs indi-
cates that autoreactive T cells that provide help to B
cells for Ab secretion are located in the secondary lym-
phoid organs and therefore are indirectly involved in
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disease pathogenesis. However, studies suggest that T
cells recruited in the joints of RA patients may be
directly involved in the initiation and propagation of
arthritis [3,5].
Induced autoimmune animal models of RA, including
collagen-induced arthritis (CIA), glucose-6-phosphate
isomerase (G6PI)-induced arthritis, and proteoglycan
(PG)-induced arthritis (PGIA), are known to involve
major histocompatibility complex (MHC) II-restricted
antigen (Ag) presentation and generation of T cells and
autoAbs that cross-react with self-(auto)Ags such as
mouse type II collagen (CII), G6PI, and mouse PG
(mPG) [6-10]. Both CIA and PGIA can be adoptively
transferred to syngeneic immunocompromised mice by
lymphocytes isolated from arthritic donors [11-13].
Despite the autoimmune pathogenesis and development
of robust and sustained inflammation of multiple joints
in CIA or PGIA, the proportion of T cells present in the
synovial fluid of these joints has been reported to be
small [14,15]. However, with regard to autoimmune dis-
eases, the consensus is that upon entry into the joints
from the bloodstream, ‘armed’ effector T cells can pro-
vide cytokine/chemokine stimuli to surrounding cells
and act in concert with these cells to trigger and main-
tain a local inflammatory process [16,17].
To address the importance of joint-homing versus
lymphoid organ-homing T cells in PGIA, we took two
experimental approaches. First, using in vivo two-photon
microscopy (TPM), we monitored the migration of
fluorescence-labeled T cells into the ankle joints and
joint-draining lymph nodes (JDLNs) of syngeneic severe
combined immunodeficient (SCID) mice during the
course of the adoptive transfer of PGIA. TPM has been
successfully used to visualize the rapid influx of T cells
into the central nervous system upon induction of
experimental allergic encephalomyelitis (EAE) [18,19],
an animal model of multiple sclerosis (MS). However, in
the adoptively transferred model of PGIA, we could
hardly detect any T cells within the synovial tissue of
the joints of SCID mice by TPM imaging either before
or after arthritis development. The lack of synovial T
cells was confirmed by immunohistochemistry (IHC)
performed on tissue sections of the same joints, but a
small population of T cells could be identified in syno-
vial fluid samples of inflamed joints by flow cytometry.
Second, to determine whether the availability of T cells
in the circulation affects their migration into the joints
and arthritis development, we used FTY720, a drug
known to ‘deplete’ T cells in peripheral blood by inhibit-
ing their exit from lymphoid organs [20-22]. FTY720, a
sphingosine 1-phosphate (S1P) receptor modulator [20],
has been found to be effective in preventing or suppres-
sing EAE in rodents [23] and shows a strong therapeutic
potential in MS [24]. In adoptively transferred PGIA, we
found that FTY720 treatment of SCID mice, transferred
with arthritic donor lymphocytes, effectively reduced
T-cell presence in both the circulation and synovial
fluid but did not inhibit or delay the transfer of arthritis.
In contrast, SCID mice receiving T cell-depleted cells
from the same arthritic donors failed to develop arthri-
tis, suggesting a strict requirement for substantial T-cell
presence for disease induction at locations other than
the peripheral joints.
Materials and methods
Mice, immunization, and assessment of arthritis
Adult female BALB/c mice and female SCID mice (on
the BALB/c genetic background) were purchased from
the National Cancer Institute (Frederick, MD, USA).
Enhanced green fluorescent protein-lysozyme M knock-
in (EGFP-LysM KI) mice (on the C57Bl/6 background)
[25] were obtained from the University of Missouri
Mutant Mouse Regional Resource Center (Columbia,
MO, USA) and were back-crossed to BALB/c for 10
generations. Mice were immunized intraperitoneally on
days 0, 21, and 42 [9,10,26] with human cartilage PG
emulsified in the synthetic adjuvant dimethyl dioctadecyl
ammonium bromide (DDA) (Sigma-Aldrich, St. Louis,
MO, USA). The paws of mice, including the ankle and
wrist joints, were inspected for signs of arthritis (swel-
ling and redness) twice a week after the third immuniza-
tion. The degree of arthritis was scored visually on a
scale of 0 to 4 for each paw (0, no swelling or redness;
1, mild swelling/redness; 2, moderate swelling of the
entire paw, including the ankle; 3, severe swelling; 4,
severe swelling with hardening of the periarticular soft
tissue). Severity was expressed as a sum of inflammation
scores (0 to 16 per mouse) as described [9,15]. Collec-
tion of human osteoarthritc cartilage (for PG isolation)
from consenting patients who had undergone joint
replacement surgery was approved by the Institutional
Review Board of Rush University Medical Center (Chi-
cago, IL, USA). Likewise, all experiments involving ani-
mals were reviewed and approved by the Institutional
Animal Care and Use Committee of Rush University
Medical Center.
Cell separation, labeling, and transfer for imaging studies
Cells were harvested under aseptic conditions from the
spleens and JDLNs (including the brachial, axillary,
inguinal, and popliteal LNs) of BALB/c mice with severe
arthritis in at least two paws. After hypotonic lysis of
erythrocytes from the spleen cell preparations, spleen
and JDLN cells were combined. T-cell enrichment was
done using Abs against non-T cell populations, followed
by immunomagnetic removal of the Ab-tagged cells
(StemCell Technologies, Vancouver, BC, Canada). The
purity of enriched T cells, assessed by flow cytometry,
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was typically 95% or greater. Non-T cells, which con-
sisted mostly of B cells (serving as Ag-presenting cells
[APCs] upon transfer into SCID mice) [13,27], were pre-
pared by immunomagnetic removal of T cells (StemCell
Technologies) from the donor population, resulting in
less than 5% T-cell contamination. Donor T cells were
labeled with a red fluorescent CellTracker dye (CMTPX;
Molecular Probes, now part of Invitrogen Corporation,
Carlsbad, CA, USA). Non-T cells (APCs) either were
left unlabeled or were labeled with the green fluorescent
CellTracker dye CMFDA (Molecular Probes) [15]. Red
fluorescent T cells were mixed with non-T cells at 1:1
to 1:3 ratios and injected intravenously into SCID mice
(2 × 107 cells per mouse). Ag (50 μg of human PG
[hPG] without adjuvant) was also injected intraperitone-
ally at the time of cell transfer to ensure in vivo re-sti-
mulation of donor cells [13,15]. Migration of fluorescent
cells to the ankle joint or to both the ankle and the
ankle-draining popliteal LN was monitored by in vivo
TPM, using SCID mice that received labeled donor cells
2 to 4 hours or 1, 2, 3, 4, 7, 12, or 18 days before ima-
ging (3 to 8 mice per time point). To visualize the entry
of freshly isolated and labeled T cells into already
inflamed joints, some SCID mice were injected first with
unlabeled donor cells. After the hindpaws became
arthritic, these mice received a second transfer of Cell-
Tracker-labeled donor cells, and the migration of fluor-
escent cells to the inflamed ankles and the popliteal LNs
was monitored by TPM. In the case of EGFP-LysM KI
BALB/c mice, which express the green fluorescent pro-
tein at high levels in neutrophils [25], only the ankle
joint was subjected to TPM upon the development of
PGIA.
In vivo two-photon microscopy
Deep-tissue imaging of the ankle joints and popliteal
LNs was performed using the Prairie Ultima two-photon
imaging system (Prairie Technologies, Middleton, WI,
USA). Before TPM, the mouse was anesthetized with a
mixture of xylazine and ketamine, and the hindlimb was
fastened to the bottom of a large-volume heated ima-
ging chamber (Bioscience Tools, San Diego, CA, USA)
using veterinary-grade super glue and adhesive strips.
The skin covering the lateral side of the ankle and the
popliteal area was surgically excised under a stereo
microscope. With a small cut on the fat tissue in
the popliteal region, the popliteal LN was brought to
the surface and held in place with a clamp applied to
the surrounding fat and muscle. Bleeding from the cuts
was modest and was stopped by cauterization. The ima-
ging chamber was filled with warm (37°C) saline and
transferred to the microscope stage. The body of the
mouse was placed on a heated pad (Fine Science Tools,
Foster City, CA, USA), and the ankle or LN was
exposed to the water-immersion objective (× 40; numer-
ical aperture 0.8) of an upright Olympus BX51WI
microscope (Olympus USA, Center Valley, PA, USA).
The temperature of both the imaging chamber and the
microscope objective (wrapped in an objective heater)
was kept constant (37°C) by programmable temperature
controllers (Bioscience Tools). Anesthesia was main-
tained by repeated injection of anesthetics (for short-
term imaging sessions) or by inhalation of isoflurane
with oxygen (for imaging sessions lasting several hours),
using a rodent inhalation anesthesia system (Protech
International Inc., Boerne, TX, USA). The two-photon
laser (Chameleon Ultra; Coherent Inc., Santa Clara, CA,
USA) was tuned to an excitation wavelength of 820 nm
for two-color imaging or 807 nm for three-color acquisi-
tion. Fluorescence emission was separated by three filter
cubes, each containing a dichroic mirror and an appro-
priate set of filters (435 to 485 nm for blue, 500 to 550
nm for green, and 570 to 625 nm for red fluorescence)
[28]. Emitted fluorescent light was detected by photo-
multiplier tubes (Hamamatsu, Hamamatsu City, Japan).
A stage motor was used to move the specimen in x, y, z
directions, and serial images were generated by axial (z)
slicing in 1- to 5-μm increments (up to 300 μm deep
into the tissue). Images (usually 512 × 512 pixels, 0.589
μm/pixel) were captured by PrairieView software (Prairie
Technologies). Since the capture of two-color images
was faster than the capture of three-color images, we
routinely used two channels for image acquisition in
SCID mice transferred with CellTracker Red-labeled T
cells along with unlabeled non-T cells. Three-color
acquisition was employed for simultaneous visualization
of CellTracker Red-labeled T cells and co-transferred
CellTracker Green-labeled APCs. In each case, one
channel was used for visualization of the ‘tissue context’
(for example, endogenous fluorescence from connective
tissue collagen) [29]. Image editing and three-dimen-
sional and four-dimensional rendering were performed
using either MetaMorph (Molecular Devices Corpora-
tion, Sunnyvale, CA, USA) or Imaris (version 6.1.3; Bit-
plane, Saint Paul, MN, USA) image processing and
analysis software.
FTY720 treatment
For treatment studies, cells were combined after isola-
tion from the spleens and JDLNs of arthritic donors but
were not subjected to any separation or labeling. These
cells (’complete’ donor population) were injected intra-
venously into SCID mice (2 × 107 cells per mouse). In
the case of T cell-depleted transfer (’negative control’
groups), T cells were removed from the same population
of donor cells by immunomagnetic separation, and the
remaining non-T cells were injected intravenously into
the SCID hosts (2 × 107 cells per mouse). Although a
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number of SCID mice receiving complete populations of
donor cells developed arthritis beginning on day 8 or 9
after transfer, we injected them once again with the
same number and same type (complete or T cell-
depleted) of donor cells between days 15 and 35 to
achieve 100% disease incidence. All cell transfers were
accompanied with intraperitoneal injection of hPG with-
out adjuvant. Cell recipient SCID mice were inspected
for arthritis symptoms every second or fourth day from
day 8 and scored for disease severity as described for
the donor BALB/c mice.
SCID mice were administered FTY720 (Cayman Che-
mical Company, Ann Arbor, MI, USA) via gavage at a
dose (1 mg/kg) reported to have a therapeutic effect in
autoimmune disease models [23,30]. FTY720 was admi-
nistered daily on the first 3 days following the first
transfer of complete donor cell populations and every
second day afterwards. Control mice also received com-
plete cell transfers and were fed with ‘placebo’ (5% etha-
nol in water). The second control group of SCID mice
(transferred twice with T cell-depleted donor popula-
tions) did not receive any other treatment. In separate
experiments, immunocompetent (wild-type) BALB/c
mice were fed with placebo or FTY720 under the same
dosing regime, beginning 1 week after the last PG injec-
tion (short-term treatment, lasting for 4 weeks) or
beginning on the day of the first PG immunization
(long-term treatment, lasting for 10 weeks). Blood sam-
ples were collected weekly from the facial veins by
means of sterile lancets, and changes in peripheral leu-
kocyte subsets (T and B cells and granulocytes) were
monitored by flow cytometry.
Histology and immunohistochemistry
The hindlimbs of mice were dissected, fixed in 10% buf-
fered formalin, decalcified, and embedded in paraffin.
Serial sections (6 μm thick) were cut, stained with
hematoxylin and eosin, and examined under a Nikon
Microphot bright field microscope (Nikon, Melville, NY,
USA). Histology images were prepared using a digital
color CCD (charge-coupled device) camera (CoolSnap;
Photometrics, Tucson, AZ, USA) and MetaMorph soft-
ware. For frozen sections, hindpaws and JDLNs of SCID
mice (transferred with red fluorescence-labeled T cells
and unlabeled non-T cells) were embedded in OCT
compound and snap-frozen. Sections (8 μm thick) were
cut on a MICROM HM 550 cryostat (MICROM Inter-
national, Walldorf, Germany) and stored at -20°C until
use. Cryosections were fixed in cold acetone and
blocked with 5% normal goat serum and 5 μg/mL anti-
CD16/32 monoclonal antibody (mAb) (Fc Block; BD
Biosciences, San Jose, CA, USA) in phosphate-buffered
saline (PBS). Sections were then probed with Alexa
Fluor 488-conjugated mAbs against CD3, CD4, or Gr-1
(BD Biosciences or eBioscience, San Diego, CA, USA).
Following post-fixation with 10% formalin, fluorescent
cells within the sections were visualized using TPM.
Cell harvest for flow cytometry
Blood samples were collected in heparin-containing
tubes, and red blood cells were eliminated by hypotonic
lysis. The white blood cell pellet was washed and pro-
cessed for flow cytometry as described below. Single-cell
suspensions were prepared separately from the spleens
and JDLNs of donor cell-reconstituted SCID mice at the
end of FTY720 treatment experiments. Synovial fluid
was harvested post-mortem from arthritic ankles by
puncturing of the lateral side of the joint with a syringe
needle. The punctured joints were subjected to gentle
pressure, and the released synovial fluid was pipetted
into Ca2+-Mg2+-free PBS. Blood-contaminated synovial
fluid samples were discarded. Synovial fluid cells were
also collected from the non-arthritic ankles of SCID
mice (which received T cell-depleted transfer) by joint
lavage. However, these joint fluid samples contained
very few cells, and lavage fluid (pooled from 8 to 10
ankles at a time) did not yield enough cells for a reliable
measurement of the cellular composition by flow cyto-
metry. Occasionally, cells were also isolated from the
synovial tissue, excised from inflamed ankles, by diges-
tion with 1 mg/mL collagenase D (Roche Diagnostics,
Indianapolis, IN, USA) at 37°C for 1 hour. Fc receptors
on leukocytes in the blood, spleen, JDLN, and synovial
cell samples were blocked with Fc Block prior to the
specific staining. Immunostaining was performed using
fluorescence-conjugated mAbs against CD45, CD3,
CD4, and B220 and occasionally against Gr-1 and
CD11b (mAbs from BD Biosciences or eBioscience).
Flow cytometry was performed using a BD FACS Canto
II instrument, and data were analyzed with FACS Diva
software (version 5.0) (BD Flow Cytometry Systems, San
Jose, CA, USA).
In vitro assays of proteoglycan-specific T-cell responses
These assays were performed as described before
[9,10,15]. In brief, spleen cells were harvested under
aseptic conditions and cultured in 96-well plates at a
density of 3 × 105 cells per well in Dulbecco’s modified
Eagle medium containing 10% fetal bovine serum in the
presence or absence of hPG (25 μg/mL) as Ag (triplicate
wells for each treatment). Half of the supernatant was
collected for interleukin-2 (IL-2) measurement on day 2
and replaced with fresh culture medium (non-stimulated
control) or with medium containing PG. Cells were cul-
tured for 6 days, and [3H]thymidine (0.5 μCi/well) was
added for the final 16 hours of culture. Cells were har-
vested using an automated harvester (FilterMate; Perki-
nElmer, Waltham, MA, USA), and isotope incorporation
Angyal et al. Arthritis Research & Therapy 2010, 12:R44
http://arthritis-research.com/content/12/2/R44
Page 4 of 16
into DNA was measured with a scintillation counter
(MicroBeta; PerkinElmer). PG-specific cell proliferation
results were expressed as stimulation index (SI) (a ratio
of isotope incorporation by PG-stimulated and non-sti-
mulated cultures). The supernatants from day 2 cultures
were incubated with IL-2-dependent CTLL-2 cells
(American Type Culture Collection, Manassas, VA,
USA), and CTLL-2 proliferation was determined by [3H]
thymidine incorporation, as described for spleen cells.
CTLL-2 cell proliferation in the presence of bioactive
IL-2, produced by PG-stimulated cultures relative to
non-stimulated cultures, was expressed as SI.
Measurement of serum proteoglycan-specific antibodies
by ELISA
Serum concentrations of PG-specific Abs from the dif-
ferent treatment groups of SCID mice were determined
by enzyme-linked immunosorbent assay (ELISA) as
described [9,10,15]. Briefly, MaxiSorp ELISA plates
(Nunc, Roskilde, Denmark) were coated with 0.75 μg/
well of hPG or 1 μg/well of mPG overnight. Unbound
material was washed out, and the wells were blocked
with 1.5% fat-free milk in PBS. Serially diluted (1:100 to
1:200,000) serum samples from individual mice and
internal standard samples (serum pooled from arthritic
BALB/c mice, containing known amounts of PG-specific
IgG1 and IgG2a) were incubated with the immobilized
PG. hPG- or mPG-specific IgG1 (or IgG2a) was detected
using horseradish peroxidase (HRP)-conjugated second-
ary Abs (Invitrogen Corporation), followed by HRP sub-
strate and o-phenylene-diamine (Sigma-Aldrich) as
chromogen. Optical densities were measured at 490 nm
using a Synergy 2 ELISA reader (BioTek Instruments,
Winooski, VT, USA). Results were expressed as milli-
grams or micrograms of PG-specific IgG/mL serum.
Statistical analysis
Statistical analysis was performed using SPSS software
(version 16; SPSS Inc., Chicago, IL, USA). Depending on
the homogeneity of variance, data were analyzed directly
or were transformed prior to analysis. Data from two
groups were compared using the independent samples
Student t test (two-tailed), and multiple group compari-
sons were made using analysis of variance with the post
hoc Dunnett t test. P values of 0.05 or less were
accepted as statistically significant.
Results
In vivo and ex vivo imaging methods reveal poor T-cell
migration into the joints during the adoptive transfer of
PGIA to SCID mice
Following intravenous injection of a mixture of CMTPX
(red fluorescent dye)-labeled T cells and unlabeled non-
T cells (APCs) or of CMTPX-labeled T cells and
CMFDA (green fluorescent dye)-labeled APCs from
arthritic BALB/c to SCID mice, we used TPM to moni-
tor donor cell recruitment in the ankle joints of the reci-
pients 1, 2, 3, 4, 7, 12, and 18 days after cell transfer.
We were unable to detect T cells in a consistent manner
in the ankle joints of SCID recipients using TPM ima-
ging (Figure 1a, c). As expected, transferred red fluores-
cent T cells (Figure 1b) or both red T cells and green
non-T cells (Figure 1d) were found in the ankle-draining
popliteal LNs at both earlier (day 2, Figure 1b) and later
(day 12, Figure 1d) time points. The SCID mouse
(whose joint and LN images are shown in the bottom
panels of Figure 1) already had arthritis in the imaged
ankle; however, no T cells were visible; only autofluores-
cent macrophages (light green) and second harmonic
generation signals from collagen fibers (blue) [29] were
detected in the synovial tissue (Figure 1c).
The virtual absence of donor T cells in the SCID
joints was not due to technical problems with fluores-
cent cell detection in the ankle by TPM given that both
CMTPX- and CMFDA-labeled cells could be visualized
if injected directly into the joint (Figure S1a in Addi-
tional file 1). Moreover, green fluorescent neutrophil
granulocytes were easily detected in the ankles of EGFP-
LysM KI BALB/c mice upon induction of PGIA (Figure
S1b in Additional file 1). In the SCID transfer experi-
ments, a donor cell occasionally could be seen moving
in the synovial blood vessels of the recipient at early
time points (up to 1 day) after injection of red CMTPX-
labeled unseparated (Figure S1c in Additional file 1) or
T cell-enriched (Figure S1d,e in Additional file 1) donor
populations. When judged on the basis of shape, motile
behavior [31], or exclusion of cytoplasmic fluorescent
dye by lobulated nuclei (Figure S1e in Additional file 1),
such cells appeared to be neutrophils rather than lym-
phocytes. The spleens of arthritic donor mice contain
only a small population (up to 6%) of neutrophils, but
these cells are subject to preferential recruitment in
synovial vessels as compared with lymphocytes [15,31].
Since transferred neutrophils do not live long in the
recipients, donor cells visualized several days after trans-
fer (Figure S1f in Additional file 1) could be lympho-
cytes. However, the frequency of donor cell appearance
in the SCID joints seemed to decrease further with time.
In contrast to a poor recruitment to the joints, red
fluorescent T cells and green fluorescent non-T cells
(mostly B cells) migrated in large numbers to the popli-
teal LNs and occupied their respective territories (Figure
1d). The frequency of donor cells visualized in the LN
did not seem to decrease with time, suggesting that
intracellular fluorescence did not fade significantly dur-
ing the 18-day time frame of TPM monitoring. Most of
the cells in the LN showed a polarized shape and
moved around vigorously during the imaging sessions
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(Supplemental video 1 in Additional file 2), as reported
by others using TPM to reveal lymphocyte motility in
mouse LNs [28,32-34].
To further investigate whether some T cells (not
detected by in vivo TPM) were present in deeper areas of
the joints of fluorescent donor cell-injected SCID mice,
we prepared serial cryosections from non-arthritic or
arthritic ankles of these mice following TPM imaging.
The sections were left unstained (to visualize red fluores-
cent T cells) or were immunostained for T cells with a
green fluorescent mAb against CD3 or CD4. Again, we
were not able to detect red fluorescent cells (unstained
section, Figure 2a) or CD3+ (not shown) or CD4+ (Figure
2b) cells in these joints (sections of inflamed synovial tis-
sue, shown in Figure 2, are from a SCID mouse with
adoptively transferred acute arthritis in the ankle). In
contrast, anti-Gr-1 staining of sections of arthritic joints
gave strong signals (Figure 2c), indicating that the major-
ity of infiltrating cells were granulocytes (neutrophils) in
the inflamed joint, as reported previously [15,31], and
neutrophils were also in the arthritic ankle of an EGFP-
LysM KI mouse (Figure S1b in Additional file 1). Next,
Figure 1 T cells or B cells, transferred from arthritic BALB/c mice to severe combined immunodeficient (SCID) mice, are detectable by
in vivo imaging in the popliteal lymph nodes (LNs) but not in the joints of the recipient mice. (a) Two-photon microscopy (TPM) image
of the ankle joint of a SCID mouse 2 days after transfer of CellTracker Red (CMTPX)-labeled T cells and unlabeled non-T cells (antigen-presenting
cells, or APCs) from arthritic BALB/c donors. No red fluorescent cells are visible in the joint. Second harmonic generation (SHG) signals from
collagen fibers (around blood vessels) are detected in the green fluorescence channel in two-color acquisition. (b) TPM image of the joint-
draining (popliteal) LN from the same mouse shows numerous red fluorescent donor T cells that homed to the LN. SHG (green) signals are from
collagen in the LN capsule and stroma. (c) TPM image of the inflamed ankle of a SCID mouse 12 days after transfer of CellTracker Red-labeled
T cells and CellTracker Green (CMFDA)-labeled APCs (>85% B cells) from arthritic donors. Although this joint was heavily inflamed, no red
fluorescent T cells (or green fluorescent B cells) were found by in vivo TPM imaging. SHG signals from collagen are detected in the blue channel
in this three-color acquisition image. Endogenous (auto) fluorescence from macrophages appears in light green. (d) TPM image of the popliteal
LN from the same mouse shows large numbers of red fluorescent T cells and green fluorescent non-T cells (mostly B cells), which occupy the
T-cell and B-cell zones of the LN, respectively. The TPM images shown are representative samples of ankle and LN images from six SCID mice
at each time point. Scale bars, 100 μm.
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we asked whether T cells in the synovial fluid of inflamed
ankles of SCID mice were detectable by flow cytometry.
Immunostaining of synovial fluid cells for CD3 and CD4
and subsequent flow cytometry revealed the presence of
a small population of T lymphocytes (mostly CD4+),
comprising less than 1% of the cells present in the joint
fluid of arthritic ankles (Figure 2d). The number of T
cells was even less (essentially negligible) when collage-
nase-digested synovial tissue samples were assayed by
flow cytometry (data not shown). As in the case of IHC,
the dominant cell population in synovial fluid of SCID
ankles was found to be Gr-1hi neutrophils that also
expressed high levels of CD11b/Mac-1 (Figure 2e), the
integrin found on leukocytes of myeloid lineage [35].
Limiting T-cell access to the joints by FTY720 treatment
after cell transfer does not inhibit arthritis development
in SCID mice, but removal of T cells before transfer does
The presence of a small population of T cells in the
synovial fluid after the development of adoptive PGIA
compelled us to investigate whether the few T cells pre-
sent in the joints played some role in the local inflam-
matory process. If so, blockade of T-cell entry from the
bloodstream into the joint could prevent or suppress
inflammation. To this end, we chose to administer oral
treatment with the S1P receptor modulator FTY720 [20]
to the SCID mice during the adoptive transfer of PGIA.
The principal mechanism of action of FTY720 is the
induction of internalization of S1P receptors (including
S1P1/S1PR1, which is highly expressed on T cells circu-
lating in blood and lymph) with subsequent loss of cell
response to S1P [21]. S1P has been shown to direct T-
cell egress from lymphoid organs [21]. Therefore, treat-
ment of animals with the S1P ‘agonist’ FTY720 or
genetic deletion of S1P1/S1PR1 renders these animals
lymphopenic [20,21], thereby preventing the entry of
lymphocytes (primarily T cells) into peripheral organs.
The immunosuppressive effect of FTY720 in some auto-
immune disease models, as well as in human MS, has
been attributed primarily to peripheral T-cell depletion
Figure 2 Immunohistochemical and flow cytometric detection of T cells and granulocytes in inflamed ankle joints of severe combined
immunodeficient (SCID) mice with adoptively transferred proteoglycan-induced arthritis (PGIA). The SCID mouse used for
immunohistochemistry developed arthritis 9 days after receiving unlabeled cell transfer and was re-transferred with CellTracker Red-labeled T
cells and unlabeled non-T cells on day 10. In vivo two-photon microscopy imaging of the inflamed ankle on day 12 revealed no red fluorescent
cells. The mouse was sacrificed, and frozen sections were prepared from the ankle after imaging. (a) No red fluorescent T cells are visible in the
unstained section of the inflamed ankle. (b) Immunostaining with green fluorophore-conjugated anti-CD4 monoclonal antibody (mAb) shows no
evidence of CD4+ T helper cells (no yellow or green color). (c) Anti-Gr-1 mAb against granulocytes stains numerous cells in the same joint. Scale
bars, 100 μm. St, synovial tissue. (d) Flow cytometry of synovial fluid cells from the arthritic ankle joints of a SCID mouse shows a small
population of T cells, nearly all of which are CD4+, in the fluid. (e) Synovial fluid from arthritic SCID ankles contains a large proportion of Gr-1hi
granulocytes that also express high levels of CD11b. Flow cytometry was done using synovial fluid samples from SCID mice that developed PGIA
approximately 2 weeks after transfer of unlabeled cells from arthritic donors. Flow data are representative of at least six synovial fluid samples
harvested from inflamed ankle joints of SCID mice with adoptively transferred PGIA.
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[23,24,30]. It was expected, therefore, that if the modest
population of joint-homing T cells had a local pro-
inflammatory role in the development of adoptive PGIA
in SCID mice, limiting their access to the joints could
inhibit inflammation.
The control (placebo-treated) and FTY720-treated
groups of SCID mice received complete cell transfer (both
T and non-T cells) from arthritic donors, and a second
control group received cells from the same donors, but
from which the T cells had been depleted prior to transfer
[13]. As shown in Figure 3a, T cells expanded in peripheral
blood in the placebo-treated SCID recipients but not in
the FTY720-treated SCID mice; both sets of mice received
complete cell transfer. In SCID mice transferred with T
cell-depleted donor populations (Figure 3a), T cells were
barely detectable in the blood 7 days after the first transfer,
but some T cells emerged in the circulation with time.
This was most likely due to homeostatic expansion of the
few T cells (’contaminants’ in the T-depleted cell fractions)
in the lymphopenic environment [13], some of which were
released into blood. However, the peripheral T-cell pool in
the T-depleted transfer groups was as small in size as the
corresponding pool in the FTY720-treated mice from day
21 after cell transfer (Figure 3a). Neither FTY720 treat-
ment nor depletion of donor T cells prior to transfer had a
strong negative impact on the percentage of circulating
B cells or granulocytes (data not shown). Surprisingly,
although FTY720 treatment kept the proportion of blood
T cells very low (approximately 1% of all CD45+ leuko-
cytes, Figure 3a), it did not prevent or delay the onset of
adoptive PGIA (Figure 3b). Placebo- and FTY720-treated
SCID mice developed arthritis with similar kinetics, and
both groups achieved 100% disease incidence within
6 weeks after the first cell transfer. In contrast, SCID hosts
transferred with T cell-depleted donor populations, despite
having as many circulating T cells as the FTY720-treated
mice from day 21 (Figure 3a), did not develop disease at
all (Figure 3b, c). FTY720 also failed to suppress arthritis
severity as the disease scores were similar in the groups
treated with placebo and FTY720 (Figure 3c).
FTY720 treatment has no effect on the development of
primary PGIA in immunocompetent BALB/c mice
To determine whether FTY720 was also ineffective in
suppressing or preventing arthritis in immunocompetent
BALB/c mice, we administered placebo or FTY720 orally
to BALB/c mice after immunizing them with PG in DDA
adjuvant to induce the primary form of PGIA. Short-
term treatment groups received placebo or FTY720 every
second day from day 49 or 50 (1 week after the third PG
injection) through day 75, and long-term treatment was
employed from the first PG immunization (day 1)
through day 70. In both cases, FTY720 quickly and signif-
icantly depleted T cells in the circulation (by greater than
90% from the first week through the end of the treatment
period). However, no delay in arthritis development was
observed in the FTY720-treated groups in either case,
and the arthritis scores were not significantly different
between placebo-treated and FTY720-treated mice
that had undergone either short-term (Figure 4a) or
Figure 3 Effects of FTY720 treatment or depletion of T cells from the transferred donor cells on circulating T cells and arthritis
development in severe combined immunodeficient (SCID) mice. SCID mice, injected with lymphocytes from arthritic donors, were subjected
to treatment with placebo (open circles) or FTY720 (closed triangles), as described in Materials and Methods. A separate group of SCID mice
received cells from the same arthritic donors, but T cells from the donor population were depleted prior to transfer (solid circles). (a) The
proportion of T cells (CD3+) among all blood leukocytes (CD45+) was monitored by flow cytometry from between day 1 after the first cell
transfer and day 42 (end of experiment). Data shown are the mean ± standard error of the mean (SEM). (n = 9 to 11 mice per group; *P < 0.01
in comparison with the placebo-treated group.) (b) The SCID mice were inspected for arthritis symptoms at 4-day intervals between days 10 and
42. Incidence of proteoglycan-induced arthritis is expressed as the percentage of arthritic animals among all SCID mice in the respective groups.
(c) The degree of inflammation in each paw was scored visually at 4-day intervals. Arthritis severity is expressed as the mean ± SEM of
cumulative paw scores (n = 9 to 11 mice per group; *P < 0.01 in comparison with both the placebo- and FTY720-treated groups).
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long-term (Figure 4b) treatment. Consistent with the
similar disease onset times and scores, histopathology of
the ankle joints on day 70 showed comparably high
degrees of leukocyte infiltration, synovial hyperplasia,
and joint tissue destruction in mice treated with placebo
(Figure 4c) and those treated with FTY720 (Figure 4d) in
the long-term experiments.
FTY720 treatment does not have an effect on the
occupancy of lymphoid organs by transferred T cells
The results of the FTY720 treatment studies suggested
that the availability of circulating T cells was perhaps
not crucial for arthritis development. This was the most
obvious in the case of adoptive transfer experiments, in
which arthritic SCID hosts, reconstituted with complete
donor populations and receiving FTY720 treatment, had
the same blood T-cell pool size (from day 21) as the
non-arthritic hosts transferred with T cell-depleted
donor fractions (Figure 3). Examination of the cellular
composition of JDLNs and spleens of SCID mice at the
conclusion of the transfer experiments (days 42 to 45)
revealed T-cell pools of comparable size in the lymphoid
organs of mice (after reconstitution with complete
donor cell fractions) treated with placebo and those
treated with FTY720 (Figure 5a, b). This finding was
consistent with the observation that FTY720 inhibits
T-cell egress from lymphoid organs but has no signifi-
cant impact on the occupancy of these organs by T cells
[20,21]. As expected, the T-cell pool in the lymphoid
organs of SCID mice, transferred with T-depleted frac-
tions from the same donors, was significantly reduced
(Figure 5a, b). This indicated that a very small number
of T cells was transferred initially, despite their subse-
quent homeostatic expansion.
Through blockade of T-cell exit from the lymphoid
organs, FTY720 was expected to limit T-cell access to the
joints. Indeed, we found the proportion (percentage) of
joint fluid T cells in the inflamed ankles of FTY720-treated
animals to be approximately half the percentage of T cells
present in the joints of placebo-treated mice (FTY720-
treated: median 0.2%, range 0.0% to 0.5%; placebo-treated:
median 0.4%, range 0.2% to 0.7%; n = 6 synovial fluid sam-
ples per group), although this difference did not reach sig-
nificance (P = 0.17). However, the degree of inflammation
was similar in the joints of FTY720-treated and placebo-
treated mice (also, see Figure 3c).
FTY720 treatment does not reduce proteoglycan-specific
T-cell responses or serum autoantibody levels, while pre-
transfer depletion of T cells completely inhibits
autoantibody production
Next, we asked whether Ag (PG)-specific T- or B-cell
responses were compromised by FTY720 treatment. As
shown in Figure 5c, proliferation of spleen T cells in
response to in vitro PG stimulation was comparable in
the placebo-treated and FTY720-treated groups but was
significantly reduced in the T cell-depleted transfer
group. Similarly, PG-specific IL-2 production (as mea-
sured by proliferation of IL-2-sensitive CTLL-2 cells) was
not impaired by FTY720 treatment but was significantly
reduced in the spleen cell cultures of SCID mice receiv-
ing T cell-depleted donor fractions (Figure 5d). The
reduced Ag-specific spleen T-cell responses in this group
of mice (Figure 5c, d) seemed to correlate directly with
the low number of T cells in the spleen (Figure 5b).
To determine whether FTY720 treatment had any
effect on Ab production, we compared serum concen-
trations of hPG-specific Abs and mPG-specific autoAbs
in the three groups of mice after termination of these
experiments (day 42 or 45). We found that SCID mice
fed with placebo or FTY720 had similar levels of IgG1
Abs against the immunizing Ag (hPG) (Figure 6a) and
that the concentration of mPG-specific autoAbs
was even slightly elevated in the FTY720-treated group
(Figure 6b). However, these Abs were completely absent
in the sera of T-depleted donor cell recipients
(Figure 6a, b; N.D.: not detectable). This was also the
case when serum samples from an additional set of
similar SCID transfer groups were assayed 67 days after
the first cell transfer, indicating that the appearance of
PG-specific Abs in serum was not simply delayed in the
T cell-depleted transfer recipients (data not shown).
Measurement of serum PG-specific Abs of the IgG2a
isotype, which were present in much smaller amounts,
revealed a similar trend, and IgG2a Abs were also absent
in serum samples of the T cell-depleted transfer group
(not shown). Since B cells were found in similar propor-
tions in the spleens of all three groups of SCID mice
(Figure 6c) as well as in the JDLNs (data not shown), the
absence of PG-specific Ab output in the T cell-depleted
transfer group could not be explained by a reduced B-cell
pool in the lymphoid organs of these mice.
Discussion
Autoimmune diseases are initiated and mediated by
autoreactive T cells that can mount a direct attack on
the target tissues or act in concert with B cells by pro-
viding help for the production of pathogenic autoAbs or
both. In animal models of MS, for example, massive
invasion of the central nervous system by ‘encephalito-
genic’ T cells has been demonstrated by different meth-
ods, including in vivo imaging [18,19]. Several
laboratories reported the presence of CD4+ T cells in
the inflamed joints in various animal models of RA, but
few studies commented on the small size of this popula-
tion relative to other leukocytes infiltrating the joints
[14,15,31,36]. CD4+ cells (both T helper 1 [Th1] and
Th17 phenotypes) are present in the rheumatoid
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Figure 4 Treatment of immunocompetent (wild-type) BALB/c mice with FTY720 has no effect on the development of the primary
form of proteoglycan (PG)-induced arthritis. (a) Short-term treatment with placebo (open circles) or FTY720 (closed triangles) started on day
49 or 50 (1 week after the third PG immunization) and ended on day 75. (b) Long-term (prophylactic) treatment was initiated after the first
immunization and ended on day 70. Data shown are the mean ± standard error of the mean of cumulative arthritis scores over time (short-term
treatment, n = 10 mice per group; long-term treatment, n = 16 mice per group; the difference between placebo- and FTY720-treated groups
was not significant in either case). (c) Histology of the ankle joint of a placebo-treated mouse from the long-term treatment group. (d) Histology
of the ankle of an FTY720-treated mouse from the long-term treatment group. Sagittal sections of decalcified and paraffin-embedded joints were
stained with hematoxylin and eosin. The degree of synovial tissue hyperplasia, leukocyte infiltration, or cartilage erosion was similar in both
joints. Scale bars, 250 μm. Bo, bone (talus); Jc, joint cavity; St, synovial tissue.
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synovial tissue and these cells are also found in smaller
numbers in the synovial fluid of affected joints of RA
patients [3,17,37,38]. On the basis of the presence of
T cells within tissue lesions in almost all forms of auto-
immune diseases, it is believed that substantial influx of
activated (effector) T cells into target organs is necessary
for the initiation and progression of disease. Therefore,
the initial aim of this study was to monitor the migra-
tion of fluorescence-labeled ‘arthritogenic’ T cells into
the joints of mice during the adoptive transfer of PGIA,
employing in vivo deep-tissue imaging with TPM, used
for the first time in an autoimmune model of RA. In
anticipation of increased T-cell traffic to the joints
around the time of arthritis onset [39], we subjected the
ankles of SCID recipient mice to TPM imaging at sev-
eral time points prior to and after disease development.
We were surprised to find that this powerful imaging
technique was unable to consistently reveal the presence
of T cells within the SCID joints at any stage of arthritis
transfer. We could detect a small population of T cells
(nearly all CD4+) in the synovial fluid of the arthritic
joints of mice by flow cytometry. The slight discrepancy
between TPM imaging and flow cytometry in the fre-
quency of fluorescent donor cell detection might be
explained by the capacity of the flow cytometer to
acquire and analyze tens of thousands of cells, whereas
only a few thousand cells (dispersed within the struc-
tural components of the joint) can be scanned by TPM.
Alternatively, instead of navigating in the synovial tissue,
some T cells may ‘flip’ directly into the fluid from the
rich network of blood vessels that are located under-
neath the synovial lining [31]. However, even in the
joint fluid, T cells represented less than 1% of infiltrat-
ing leukocytes, most of which were neutrophils.
Figure 5 Proportion of lymphoid organ-homing T cells and magnitude of antigen (Ag)-specific T-cell responses in severe combined
immunodeficient (SCID) mice treated with placebo or FTY720 after receiving complete donor lymphocyte transfer (T cells along with
non-T cells as Ag-presenting cells) and in SCID mice receiving T cell-depleted transfer. T-cell proportions in the (a) joint-draining lymph
nodes (JDLNs) and (b) spleens were measured by flow cytometry and expressed as percentage of CD3+ of total CD45+ cells. Data shown are the
mean ± standard error of the mean (SEM) (n = 9 to 11 mice per group; *P < 0.05). (c) Ag (human proteoglycan)-specific spleen cell proliferation
and (d) Ag-specific production of bioactive interleukin-2 (IL-2) by the same spleen cell cultures were assayed on the basis of [3H]thymidine
incorporation into splenocytes and CTLL-2 cells, respectively. Results are expressed as stimulation index and are the mean ± SEM (n = 4 to 5
mice per group; *P < 0.01). Isotope incorporation by non-stimulated cell cultures was less than 1,700 cpm per well and was comparable among
the three groups of mice. PG, proteoglycan.
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To further investigate whether limiting the access of
T cells to the joints would delay or suppress arthritis, we
employed oral treatment with FTY720, an S1P receptor
modulator that inhibits T-cell egress from the lymphoid
organs [22] and subsequent entry of these cells into target
tissues via the blood circulation. This mechanism of
FTY720 treatment has been postulated to account for dis-
ease suppression in animal models of MS (and in patients
with MS) and autoimmune diabetes [23,24,30]. Although
we found that FTY720 effectively depleted T cells in the
circulation and reduced T-cell presence in the synovial
fluid, it failed to inhibit the development or reduce the
severity of PGIA in either the primary or the adoptively
transferred form of the disease. These results do not seem
to be consistent with the report by Wang and colleagues
[40], in which treatment of chicken CII-immunized rats
with FTY720 significantly suppressed the development of
CIA. Since blood T cells were depleted to a similar extent
by FTY720 in rat CIA [40] and murine PGIA (Figure 3a),
the discrepancy between their study and ours can be
explained only by assuming that pathogenic T cells
migrate to the joints in much larger numbers and have a
much greater role in the local inflammatory process in
rats with CIA than in mice with PGIA. This is a distinct
possibility as Wang and colleagues [40] could identify
numerous CD4+ cells in the inflamed joint tissue of CIA
rats by IHC, whereas we could detect essentially none in
adoptively transferred PGIA by means of a similar method.
In murine CIA, however, Holmdahl and colleagues [14]
reported that T cells constitute a minor population of
joint infiltrating cells. Also, in earlier studies on CIA in
DBA/1 mice ([41] and our unpublished data) and on
PGIA in BALB/c mice [15,31], we found that the propor-
tion of joint-homing T cells is low in both models, sug-
gesting that the paucity of these cells in arthritic joints is
not a unique feature of PGIA.
The role of joint-infiltrating T cells in the pathology of
RA has been a matter of debate for decades. On the basis of
very low T-cell cytokine levels in rheumatoid synovial sam-
ples [42] and the hyporesponsiveness of joint-infiltrating T
Figure 6 Concentrations of proteoglycan (PG)-specific serum antibodies and percentages of spleen B cells in severe combined
immunodeficient (SCID) mice treated with placebo or FTY720 after receiving complete donor lymphocyte transfer and in SCID mice
receiving T cell-depleted transfer. Serum levels of (a) human PG (hPG)-specific antibodies and (b) mouse PG (mPG)-specific autoantibodies of
the IgG1 isotype were determined by enzyme-linked immunosorbent assay and expressed as milligrams per milliliter and micrograms per
milliliter, respectively. N.D., not detectable. (c) The proportion of B cells in the spleens of the three groups of SCID mice was measured by flow
cytometry and expressed as percentage B220+ of total CD45+ cells. Data shown are the mean + standard error of the mean (n = 9 to 11 mice
per group).
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cells to T-cell receptor stimulation [43], earlier studies have
questioned the impact of synovial T cells on the local
inflammatory process. More recent reports have identified
‘pro-inflammatory’ Th1 and Th17 cells as well as ‘anti-
inflammatory’ regulatory T cells (Tregs) in rheumatoid
joints (reviewed in [3]). Tregs have also been found in
inflamed synovial fluid samples of patients with juvenile
idiopathic arthritis and various forms of spondylarthropathy
[44], suggesting that some T cells, such as Tregs, might be
attracted to sites of inflammation, where these Tregs should
have a protective, rather than a destructive, role [44]. Pro-
gression of inflammatory joint destruction in the absence of
synovial T cells has been reported in an RA patient with
advanced HIV infection [45], highlighting the strong invol-
vement of T cell-independent processes and non-T cells in
the joint pathology of RA. In serum or Ab transfer-induced
models of RA, transient arthritis develops apparently in an
(autoreactive) T cell-independent manner and is character-
ized by massive influx of neutrophils into the joints of naïve
recipient mice [46,47]. Interestingly, a minor T-cell popula-
tion was also found in the synovial fluid of naïve mice after
induction of arthritis by serum transfer, and Tregs were
identified as a prominent population of these joint-homing
T cells [48]. As in the case of Tregs found in arthritic joints
of patients with RA and other arthropathies [44], the pre-
sence of Tregs in the joints of naïve animals after passive
transfer of arthritis argues for a secondary recruitment of
these T cells to the site of inflammation.
Although PGIA does not appear to be inducible via
serum transfer ([12] and our unpublished data), neutro-
phils still vastly outnumber T cells in the inflamed joints
in PG-immunized arthritic BALB/c mice and in SCID
mice with the adoptively transferred form of the disease
[15,31]. As we demonstrate in this study, it is easy to iden-
tify Gr-1hi cells, in contrast to T cells, in both synovial tis-
sue and fluid samples of inflamed ankle joints of SCID
mice with adoptively transferred PGIA. Cell depletion
experiments indicate that neutrophils are directly involved
in the local inflammatory and destructive processes as
anti-Gr-1 mAb-mediated elimination of circulating neu-
trophils promptly abrogates arthritis in both PGIA [49]
and a serum/Ab transfer-induced model of RA [47].
In contrast to neutrophil depletion, our study demon-
strates that reduction of circulating T cells by FTY720
treatment does not have a significant effect on disease
onset or severity in PGIA. Since FTY720 treatment signifi-
cantly lowered the number of circulating T cells but did
not completely eradicate them from the blood or from
joint effusions, the conclusion that can be drawn from this
part of our study is that the initiation and effector phases
of PGIA are quite independent of the availability of T cells
in the circulation. Transfer of arthritogenic donor cells,
from which T cells had been depleted prior to injection
into the SCID mice, however, did not result in arthritis,
suggesting that substantial T-cell presence in the recipi-
ent’s immune system (but not in the joints) was an abso-
lute requirement for disease development.
The absence of PG-specific (including autoreactive)
serum Abs in mice receiving T-depleted cell transfer,
despite a B-cell pool of normal size, indicates a require-
ment for robust T-cell help for effective production of
Ag-specific Abs by B cells. The reduced size of T-cell
pool found in the lymphoid organs and the lack of circu-
lating PG-specific Abs suggest that B cells did not receive
adequate T-cell help in these mice. Furthermore, the lack
of PG-specific Abs (and mPG-specific autoAbs, in parti-
cular) in the serum and the concomitant absence of
arthritis in the T cell-depleted transfer groups indicate an
important contribution of these Abs to disease develop-
ment. Indeed, autoAbs have been shown to be patho-
genic in autoimmune models of RA [27,50,51] as serum
Abs against murine CII, G6PI, or other autoAgs can
induce transient arthritis when injected into naïve mice
[46,51,52]. Deposition of autoAg- and IgG-containing
immune complexes (ICs) in the joints has been repeat-
edly reported in RA and serum/Ab-induced arthritis
models [2,53-56]. Some Abs, which may access the joints
by crossing ‘leaky’ synovial blood vessels [56], remain
associated with autoAgs expressed locally in the joint (for
example, proteins present on the surface of articular car-
tilage or in the synovial fluid). The role of ICs in comple-
ment fixation is well known, as is the involvement of ICs
and complement fragments in the rapid recruitment of
Fc receptor-bearing phagocytic cells (neutrophils and
monocytes) in the joint from the circulation, leading to
tissue infiltration and swelling [43,46,53,55,57]. Although
neither immune serum nor T cells or B cells (from
arthritic animals) appear to be capable of transferring
PGIA to SCID mice when injected alone [12,13], mild
and transient synovitis is observed after co-injection of
immune serum and T cells (but not B cells), and this
mild inflammation can even be extended by repeated
administration of immune serum ([27] and our unpub-
lished data). This observation suggests that arthritogenic
Abs and T cells may briefly synergize to initiate inflam-
mation but that continuous in vivo production of auto-
Abs by B cells (probably in a T cell-supported manner)
is necessary for the perpetuation of the inflammatory
process and establishment of chronic disease.
Conclusions
Here, we show that the development of autoimmune
arthritis in an animal model of RA is not accompanied
by a robust influx of T cells into the joints and that
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inflammation is rampant even if the availability of circu-
lating T cells is profoundly reduced. Arthritis does not
develop when T-cell presence is also reduced in the sec-
ondary lymphoid organs, in which case autoAbs are not
detected in the circulation. According to these observa-
tions, the major contribution of T cells to joint inflam-
mation stems from their capacity to provide help to
B cells within the lymphoid organs for systemic produc-
tion of pathogenic autoAbs. Although some rare joint-
infiltrating T cells may have a role in the recruitment of
other leukocytes (neutrophils and monocytes), the local
inflammatory process appears to be dependent on the
availability of circulating autoAbs (and neutrophils)
rather than T cells. As discussed above, strong depen-
dence of arthritis on autoimmunity, but limited or no
dependence on local T cells, is observed (or at least sus-
pected) in other animal models of RA. Whether this is a
paradox restricted to animal models or is also a paradox
of the human disease (for example, in patients with ser-
opositive forms of RA) remains to be determined.
Additional file 1: Supplemental Figure 1 (Figure S1). Technical issues
with in vivo joint imaging and rare cases of donor cell appearance in
SCID joints after cell transfer. (a) Fluorescence-labeled cells injected
directly into the joint cavity can be easily visualized by TPM. A mixture of
CMTPX (red) and CMFDA (green)-labeled lymphocytes (~1,000 cells) was
injected into the cavity of the ankle joint of a BALB/c mouse. The joint
was subjected to TPM imaging 2 days after the intra-articular cell
injection. Red and green fluorescent cells are visible in the joint in the
vicinity of connective tissue (blue). (b) EGFP-expressing granulocytes
(neutrophils) are abundant in the joints of EGFP-LysM KI mice with acute
PGIA. Mice with EGFP knocked in the lysozyme M locus (EGFP-LysM KI),
which express this fluorescent protein in their granulocytes at very high
levels, were backcrossed into the BALB/c background and immunized to
induce PGIA. TPM imaging was performed on the arthritic ankle joint 2
days after disease onset. Numerous green fluorescent cells are visible in
the synovial tissue and cavity. (c) Fluorescence-labeled donor cells
appear in the circulation of recipient SCID mice at early time points after
transfer. Unseparated spleen-LN cells from arthritic donor mice were
labeled with red CMTPX and injected i.v. into SCID recipients. TPM
imaging of the ankle joint was carried out on the day following cell
transfer. A single red fluorescent cell (arrow) is visible at a branching
point of synovial blood vessels. Time-lapse video revealed a motility
pattern that was similar to the behavior of neutrophils in EGFP-LysM KI
mice, making uncertain that the red cell was a lymphocyte. (d-f) Donor
cells are occasionally found in the synovial tissue or vessels after transfer
of T cell-enriched fractions. (d) A red fluorescent cell (arrow) is visible in
the synovial tissue 1 day after i.v. transfer of CMTPX-labeled T cells (along
with CMFDA-labeled APCs) from arthritic donors to a SCID mouse. (e)
High-magnification imaging of the midsection of the same immobile red
cell (boxed in panel d) revealed the presence of cytoplasmic ‘holes’
corresponding to nuclear lobes. This raised the suspicion of this red cell
being a polymorphonuclear leukocyte from the donor spleen cell
preparation. (f) This SCID joint was imaged 4 days after the transfer of
CMTPX-labeled T cells and unlabeled APC from arthritic donors. A single
red cell (arrow) is seen within the shadow of a blood vessel. Serial
images showed tethering-rolling movement of this red cell along the
vessel walls, indicating that it was located intravascularly. The presence of
donor cells in the recipients’ joints was not typical, and was even less
frequent at later time points (days 7-18) after transfer. Scale bars, 50 μm.
Additional file 2: Supplemental Video 1. Localization and motility of
fluorescent T and B cells in the popliteal LN of a SCID mouse following
their transfer from arthritic BALB/c mice. Donor T cells were labeled with
CellTracker Red (CMTPX) and non-T cells (~90% B cells) with CellTracker
Green (CMFDA), and mixed at a ratio of 1:2 prior to injection into the
SCID mouse. The popliteal LN was subjected to TPM imaging on day 7
after cell transfer. Z series of images were acquired from the LN in vivo.
Autofluorescent subcapsular sinus macrophages (light blue) are seen in
the top layer of the cortex. B cells (green) localize in the more superficial,
while T cells (red) in the deeper areas of the LN. Most T and B cells
exhibit a polarized shape and ‘random’ movement. Imaging depth: 87
μm; time elapsed: 9.5 min.
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